Lower-dose psycholytic therapy – A neglected approach

This review (2022) makes the case for lower dose (75-125μg) LSD with multiple sessions (5-8x) in combination with talk therapy. 15 years of use in Europe in the 1960s is explored to define the features of psycholytic therapy.

Abstract

Lysergic acid diethylamide (LSD) and similar psychoactive drugs have been used in psychotherapy since 1949, when the first clinical study with lower-dose LSD showed therapeutically relevant effects. This caused an intense interest among psychotherapists and researchers, alike, on an international scale. In 1960, the use of serial lower-dose LSD/psilocybin sessions in a psychoanalytical framework, which was dominant at the time, was named “psycholytic therapy”. Psycholytic therapy was usually conducted in clinical environments, on both an inpatient and outpatient basis. Psycholytic therapy was developed and established over a 15-year period on the European continent, where it was used at 30 clinical treatment centers and by more than 100 outpatient psychotherapists. Psycholytic approaches were employed minimally in North America, where the psychedelic approach (use of one or two high-dose sessions for “personality-transforming mystical experiences”) became the dominant method in use. The leading figure in psycholytic therapy was Professor Hanscarl Leuner in Germany, who laid the ground with his uniquely fine grained analysis of the LSD reaction in a 1962 monograph. He was central in establishing and distributing psycholytic therapy in Europe and abroad. The article provides comprehensive background information and outlines the essential features of psycholytic therapy. Evidence for the efficacy of psycholytic therapy is reviewed and a case for the inclusion of the psycholytic approach in the field of substance-assisted psychotherapy is made.

Authors: Torsten Passie, Jeffrey Guss & Rainer Krähenmann

Summary of Lower-dose psycholytic therapy

Abram Hoffer and Humphrey Osmond developed the psychedelic treatment technique, which uses high dosages, specific surroundings, and music to induce transformational insights and mystical experiences. However, no controlled efficacy studies showed significant results in favour of psychedelic peak therapy for alcoholism or chronic neuroses.

Recent RCT studies are solely focused on the psychedelic approach, which may help explain why psycholytic therapy is underutilized and undertheorized in the contemporary psychedelic research scene.

PDF of Lower-dose psycholytic therapy

Authors

Authors associated with this publication with profiles on Blossom

Torsten Passie
Torsten Passie has done work on the psychedelic experience (altered states of consciousness) and the pharmacology of hallucinogenic drugs. He is currently a visiting professor at Harvard Medical School.

Jeffrey Guss
Jeffrey Guss is a psychiatrist, psychoanalyst, and researcher with a specialization in the treatment of substance use disorders. He is a clinical assistant professor of psychiatry at the NYU School of Medicine.

Linked Research Papers

Notable research papers that build on or are influenced by this paper

A Psychoanalytic Perspective on Psychedelic Experience
This perspective (2022) provides an understanding of the psychedelic experience through 1) ego dissolution and mystical states, 2) hyperassociative states, and 3) the role of set and setting.

PDF of Lower-dose psycholytic therapy – A neglected approach